This trial is evaluating whether CBOT + TAU will improve 6 primary outcomes and 7 secondary outcomes in patients with Craving. Measurement will happen over the course of Screening visit to Week 2.
This trial requires 190 total participants across 2 different treatment groups
This trial involves 2 different treatments. CBOT + TAU is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
"Opioid use is a major and frequent cause of death in the United States. Alcohol and marijuana use may also contribute to the frequency and complexity of opioid use and abuse. The major route of opiate use is through the sale or diversion of illicit pharmaceutical drugs, particularly morphine, methadone and heroin. Drug users face multiple social and health disparities. As opioid use increases, the rate of misuse and abuse increases. Effective treatment and prevention programs could have the most benefit. Educational and economic information is vital for mitigating the harm of opioid use. Understanding that individuals who choose these drugs are at greater risk of abuse has an important role in treatment and prevention programs." - Anonymous Online Contributor
"It is impossible to cure opioid abusers. The idea of eradicating their addiction is unrealistic and, in general, this is an unrewarding path for the individual and for public health policy. To the extent that an addict might be cured, the effect will be negligible." - Anonymous Online Contributor
"About half of opioid abusers abuse prescription opioids, which suggests use of these drugs is a highly prevalent issue. More than one in four addicts in a one-year period had been in treatment for more than one year and one out of five abuse is for nonmedical purposes. While a large majority of addicts are aware of the negative impacts of their misuse, little of the available evidence-based treatments are being offered in outpatient rehabilitation for illicit drug problems. Effective and sustained intervention programs focusing on pharmacotherapeutic components are needed." - Anonymous Online Contributor
"This report provides a compendium of common signs of opioid abuse and a basic guide and algorithm for the clinical detection of indicators of opioid abuse. Further studies are needed that assess other possible signs of opioid abuse outside of common signs." - Anonymous Online Contributor
"About 11.4 million people in the United States receive treatment at least once yearly for opioid abuse while 3.3 million get diagnosed annually. This is a substantial number for those who get this kind of treatment." - Anonymous Online Contributor
"The CBT + tau combination appears to be safe and effective with little difference in the rate of recidive psychosis (relative risk) compared to either individual treatment in a large, prospective, open-label, unblinded trial." - Anonymous Online Contributor
"The prevalence of opioid abuse in Canada is high. Although some patients use opioids strictly for medical reasons and others for recreational purposes, the majority of patients in the study were abusing opioids for reasons other than medical ones. This report demonstrates the need for a national system of prescription reporting, in the hopes that this information will lead to more adequate public education and policy." - Anonymous Online Contributor
"Results from a recent paper demonstrate that Cbot + tau effectively controlled, and provided a significant benefit in terms of pain relief, in patients with peripheral neuropathy secondary to chronic diabetic foot ulcer. The addition of Cbot + tau is most effective in individuals with poor kidney function and those on diuretics." - Anonymous Online Contributor
"There are no medications currently approved by the FDA for the treatment of BZD abuse. Combinations of bupropion and a taurine derivative such as CBT + Tau have been reported to be effective in treating BZD abuse at least in part by decreasing the dopamine levels within the brain. However, more studies are needed. It is important to understand that CBT + Tau does treat BZD. However, it probably is not going to be a cure. BZD use is the strongest drug risk factor for drug addiction and overdose of a pharmaceutical; thus, the use of CBT + Tau is only a first step toward a drug abuse treatment." - Anonymous Online Contributor
"Although these findings are intriguing as they underscore the potential importance of environmental factors and genes for the etiology of addictive behavior, the evidence also points to the need to be cautious in interpreting and comparing family and cohort studies of liability for prescription drug abuse." - Anonymous Online Contributor
"The present trial does not refute a possible clinical superiority of combined buprenorphine/naloxone over a placebo with respect to treatment of pain associated with opiate dependence. The findings have to be validated in a further study with a relatively bigger sample sized." - Anonymous Online Contributor
"There was no evidence of an increased risk of overdose with CBOT+Tau use or a significantly reduced risk of overdose with RIGA use. This may be because those at risk with a previous overdose were unlikely to use the treatments on subsequent occasions." - Anonymous Online Contributor